Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 236 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antipsychotic therapy Clear all
Completed Phase 3 Interventional Results available

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

NCT02013622
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Cerritos, California • Chula Vista, California • Costa Mesa, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 26, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

NCT04856124
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Intranasal esketamine
Drug
Lead sponsor
Psych Atlanta
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Specialized Treatment Early in Psychosis (STEP)

NCT00309452
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features
Interventions
Cognitive Behavioral Group Therapy, Cognitive remediation, Medications, MFG, Assertive case management, Treatment as Usual in the community
Behavioral · Drug · Other
Lead sponsor
Yale University
Other
Eligibility
16 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis

NCT04373590
View directory record Official record
Conditions
Early Psychosis
Interventions
Decision aid
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 4 Interventional

Treatment of Obsessive-Compulsive Disorder

NCT00000373
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
olanzapine + fluoxetine, placebo + fluoxetine
Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 26, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

NCT00977522
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-03463275, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
37
States / cities
Cerritos, California • Chula Vista, California • Escondido, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 4 Interventional

Treatment for First-Episode Schizophrenia

NCT00000374
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
16 Years to 40 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
2
States / cities
Glen Oaks, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

NCT01235520
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
30
States / cities
Little Rock, Arkansas • Buena Park, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 26, 2026, 10:10 PM EDT
Recruiting Phase 3 Interventional

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

NCT06482554
View directory record Official record
Conditions
Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions
Lumateperone 42 mg, Risperidone 2 mg
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

VA Augmentation and Switching Treatments for Improving Depression Outcomes

NCT01421342
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

NCT02970305
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

NCT00498550
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Abuse
Interventions
Clozapine, Treatment as usual
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Kansas City, Missouri • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 26, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy

NCT00399776
View directory record Official record
Conditions
Adolescent Depression
Interventions
Bone Density Test
Radiation
Lead sponsor
Creighton University
Other
Eligibility
10 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

NCT05542264
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

NCT01157351
View directory record Official record
Conditions
Schizophrenia
Interventions
paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
55
States / cities
Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

NCT03526354
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
Interventions
Brexpiprazole, Treatment as Usual
Drug · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Augusta, Georgia • Boston, Massachusetts • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Patient-Centered Medication Adherence Intervention for Schizophrenia

NCT00144027
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic medication adherence intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
No. Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

NCT01552772
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

NCT00412373
View directory record Official record
Conditions
Schizoaffective Disorder, Psychotic Disorder
Interventions
Placebo, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
15
States / cities
Cerritos, California • Costa Mesa, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

NCT00556140
View directory record Official record
Conditions
Psychotic Depression
Interventions
Aripiprazole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)

NCT00790517
View directory record Official record
Conditions
Weight Loss, Diabetes Mellitus, Type 2, Psychotic Disorders
Interventions
Premier Lifestyle Intervention with DASH Diet
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clozapine Therapy Sample Collection - Method Comparison Study

NCT05422131
View directory record Official record
Conditions
Patients Prescribed Clozapine
Interventions
MyCare Insite Clozapine Test
Device
Lead sponsor
Saladax Biomedical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 26, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Allopurinol Add-on Treatment for Refractory Mania

NCT00643123
View directory record Official record
Conditions
Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 26, 2026, 10:10 PM EDT